CN105520137A - Healthy food with functions of relieving asthenopia and protecting eyesight - Google Patents
Healthy food with functions of relieving asthenopia and protecting eyesight Download PDFInfo
- Publication number
- CN105520137A CN105520137A CN201510963918.0A CN201510963918A CN105520137A CN 105520137 A CN105520137 A CN 105520137A CN 201510963918 A CN201510963918 A CN 201510963918A CN 105520137 A CN105520137 A CN 105520137A
- Authority
- CN
- China
- Prior art keywords
- oil
- vitamin
- food
- health food
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 36
- 230000004438 eyesight Effects 0.000 title claims abstract description 35
- 230000006870 function Effects 0.000 title abstract description 19
- 235000001497 healthy food Nutrition 0.000 title abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000003921 oil Substances 0.000 claims abstract description 21
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 18
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 17
- 239000008158 vegetable oil Substances 0.000 claims abstract description 17
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 16
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 16
- 239000011719 vitamin A Substances 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- 229940045997 vitamin a Drugs 0.000 claims abstract description 16
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940046009 vitamin E Drugs 0.000 claims abstract description 15
- 235000019198 oils Nutrition 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims description 40
- 239000002775 capsule Substances 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000004040 coloring Methods 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 108010010803 Gelatin Proteins 0.000 claims description 14
- 229920000159 gelatin Polymers 0.000 claims description 14
- 239000008273 gelatin Substances 0.000 claims description 14
- 235000019322 gelatine Nutrition 0.000 claims description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 14
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 8
- 235000012424 soybean oil Nutrition 0.000 claims description 8
- 235000019774 Rice Bran oil Nutrition 0.000 claims description 7
- 239000008165 rice bran oil Substances 0.000 claims description 7
- 239000002285 corn oil Substances 0.000 claims description 5
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 239000003813 safflower oil Substances 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract description 28
- 235000012680 lutein Nutrition 0.000 abstract description 24
- 229960005375 lutein Drugs 0.000 abstract description 24
- 239000001656 lutein Substances 0.000 abstract description 24
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract description 24
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract description 24
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 2
- 229940026314 red yeast rice Drugs 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 30
- 208000024891 symptom Diseases 0.000 description 24
- 230000004310 photopic vision Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000009534 blood test Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 238000002562 urinalysis Methods 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 230000002402 anti-lipaemic effect Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000002189 macula lutea Anatomy 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- 102000004330 Rhodopsin Human genes 0.000 description 4
- 108090000820 Rhodopsin Proteins 0.000 description 4
- 206010047513 Vision blurred Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000035614 depigmentation Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 3
- 244000078534 Vaccinium myrtillus Species 0.000 description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000000695 crystalline len Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 235000020945 retinal Nutrition 0.000 description 3
- 239000011604 retinal Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000009847 Eye Foreign Bodies Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 240000007509 Phytolacca dioica Species 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- -1 oxygen free radical Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 239000004233 Indanthrene blue RS Substances 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241001025261 Neoraja caerulea Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000000873 fovea centralis Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940106231 lutein 6 mg Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- ZJHHPAUQMCHPRB-UHFFFAOYSA-N urea urea Chemical compound NC(N)=O.NC(N)=O ZJHHPAUQMCHPRB-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a healthy food with functions of relieving asthenopia and protecting eyesight. The healthy food with functions of relieving asthenopia and protecting eyesight comprises the following active components in percentages by weight: 20-30% of lutein oil, 10-20% of red yeast rice, 0.4-1% of vitamin A, 0.5-1% of vitamin E, and 48-69.1% of vegetable oil. According to the healthy food with functions of relieving asthenopia and protecting eyesight, a certain synergistic effect is achieved among the components through the specific compatibility and proportion of each component, so that the healthy food has functions of relieving asthenopia and protecting eyesight, and also has functions of assisting in lowering blood fat and regulating cardiovascular system.
Description
Technical field
The present invention relates to field of health care food, particularly a kind of health food with alleviating asthenopia and vision protection function.
Background technology
Visual fatigue, also known as kopiopia, is based on the subjective symptoms of patient's eye, the syndrome that eye or whole body apparatus factors are interweaved with spirit (psychology) factor.Asthenopic symptom has that eye is dry and astringent, foreign body sensation, eyelid sense of heaviness, blurred vision, photophobia are shed tears, eye distending pain etc., also can there is katzeniammer, One's spirits are drooping, absent minded, the whole body syndrome such as decrease of memory, poor appetite and neck aching pain in waist and back in severe patient, teenager also can occur myopia or deepen original myopic degree etc.
In communication society, the video display terminal (vdt) such as computer, television set has been deep in daily life, and the series of problems such as the visual fatigue thereupon occurred get more and more.Research display, the asthenopic age occurred frequently be 21-50 year, the crowd of this age bracket is large by eye intensity, work strain, makes eyes be in adjustment Set Status for a long time, easily produces fatigue.With constantly extending between at the moment, intensity increases, frequent operating computer or work before fluorescent screen for a long time, become the key factor that current visual fatigue is shy with strangers.In addition, the incidence of disease of the elderly's eye disease also increases year by year.According to investigations, the eye macula lutea relevant to the age moves back damage sex change (AMD) and has exceeded the illness in eye such as glaucoma, detachment of retina, becomes the elderly's visual impairment and blind first cause, more than 50 years old in crowd, this sick incidence of disease about 15.5%, wherein has 5.1% blinding.
In the market there is raw material that in the health food of alleviating asthenopia, vision protection function, most of product is used mainly based on the fruit of Chinese wolfberry, chrysanthemum, Bilberry fruit P.E, blueberry extract etc.; though this series products never same-action mechanism plays the effect of alleviating asthenopia, there is effect not directly effectively, the many disadvantages of the aspects such as comparatively large, the difficult quality control of dose.A kind of health food with alleviating asthenopia and preparation method thereof disclosed in Chinese patent 201210283713.4, comprises Bilberry fruit P.E 130 ~ 200 parts, 40 ~ 70 parts, lutein, 15'-dioxygenase ~ 28 part, zinc gluconate 70 ~ 112 parts.This health food take Bilberry fruit P.E as primary raw material, ophthalmodynia can be alleviated, eye is swollen, symptom that photophobia, blurred vision, eye are dry and astringent, wherein not too effective for the dry and astringent improvement situation of eye, improvement rate is only 26.53%, not mentioned for the improvement effect of eye foreign body sense in addition.
Therefore; along with the asthenopic number of China was that geometry number increases in recent years; the rising of some eye disease incidences of disease; the vision health idea of people is also more and more stronger; invention one has the clear and definite mechanism of action, easily absorption, alleviating asthenopia more remarkable effect, can prevent the illness in eye such as AMD; the health food of vision protection is one of this area problem demanding prompt solution.
Summary of the invention
For above-mentioned the deficiencies in the prior art, the invention provides a kind of health food with alleviating asthenopia and vision protection function.
First aspect; a kind of health food with alleviating asthenopia and vision protection function provided by the invention; its active ingredient comprises following component by weight percentage: xanthophyll-oil 20% ~ 30%; red colouring agent for food, also used as a Chinese medicine 10% ~ 20%; vitamin A 0.4% ~ 1%, vitamin E 0.5% ~ 1% and vegetable oil 48% ~ 69.1%.
Preferably, described vegetable oil is any one or a few the combination in soybean oil, sunflower oil, olive oil, safflower oil, rice bran oil and maize germ oil.
Preferably, described vegetable oil is corn oil, and the percentage by weight of each component is: xanthophyll-oil 20%, red colouring agent for food, also used as a Chinese medicine 10%, vitamin A 0.4%, vitamin E 0.5% and vegetable oil 69.1%.
Preferably, described vegetable oil is soybean oil, and the percentage by weight of each component is: xanthophyll-oil 25%, red colouring agent for food, also used as a Chinese medicine 15%, vitamin A 0.6%, vitamin E 0.8% and soybean oil 58.6%.
Preferably, described vegetable oil is rice bran oil, and the percentage by weight of each component is: xanthophyll-oil 30%, red colouring agent for food, also used as a Chinese medicine 20%, retinol1 %, vitamin e1 % and rice bran oil 48%.
Preferably, the formulation of health food is capsule, and the mass ratio of active ingredient and capsule material is: 1:1.8.
Preferably, described capsule material comprises gelatin, glycerine, water and Brown Ferric Oxide, and the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.
Second aspect, a kind of health food with alleviating asthenopia and vision protection function provided by the invention, comprise active ingredient and capsule material, described active ingredient comprises following component by weight percentage: xanthophyll-oil 20% ~ 30%, red colouring agent for food, also used as a Chinese medicine 10% ~ 20%, vitamin A 0.4% ~ 1%, vitamin E 0.5% ~ 1%, and vegetable oil 48% ~ 69.1%; The mass ratio of described active ingredient and capsule material is: 1:1.8.
Preferably, described capsule material comprises gelatin, glycerine, water and Brown Ferric Oxide, and the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.
The compatibility mechanism of health food of the present invention comprises:
Lutein: lutein (Lutein) belongs to one of carotenoid, it is one of main composition composition of the phytochromes such as flowers, fruit, vegetables, it is the main component of macula retinae in eyes simultaneously, the carotenoid existed only in retina, be that human body cannot synthetic, can only obtain from food.Macula lutea is positioned at the middle position of eye ground, and be the position of the sharpest and most critical of the vision of people, be mainly used in epicritic vision, identification colors, once macula lutea is impaired, eyesight will be subject to badly damaged, cause irreversible central light loss, finally cause blind.
Lutein gathers at fundus flavimaculatus position, provides the pigment required for macula lutea, stops ultraviolet to produce singlet oxygen to eye injuries.Adult human retina macula lutea is the photosensory cell concentration zones of ocular region central vision energy perception, and this region subjects inevitable eremacausis and coerces, and along with the age increases, can cause visual impairment.In fovea centralis concentration zones, be lutein optium concentration concentration zones, the blue ray that more multipair retina has damage force most can be absorbed.Generated to suppress free radical by quenching singlet oxygen, there is polyunsaturated fatty acid oxidative deformation in protection and prevention retina cell.
The supplementing blurred vision of lutein, the symptom such as eye is dry and astringent, eye is swollen, ophthalmodynia, photophobia have clear improvement; Supplement the lutein of q.s in time, can prevent the aging of macula retinae, the generation of prevention AMD disease, takes in lutein 6mg every day, then the risk of AMD disease morbidity can reduce by 43%; Lutein can deposit in the crystalline lens of eye, suppresses cataractous development, if take in the lutein of q.s, women, the male sex suffer from cataractous risk can reduce by 22%, 19% etc. respectively
Lutein exists in two forms, i.e. free lutein and lutein ester.Both can reach the effect of nutritional supplementation equally, but lutein ester needs through body metabolism, just can be absorbed by the body after being translated into free lutein, and therefore, compared with lutein ester, the absorption rate of free lutein crystal is higher.
The lutein raw material adopted in various embodiments of the present invention is xanthophyll-oil.Xanthophyll-oil is according to lutein (molecular formula C
40h
56o
2) character water insoluble, the crystal lutein extracted from marigold is scattered in (as: safflower oil, soybean oil, sunflower seeds wet goods) in vegetable oil, and add a certain amount of dl-alpha-tocopherol as antioxidant, the viscous oily liquid made.While can reducing crystal lutein generation oxidation reaction like this, the stability of protection crystal lutein, improves the absorptivity of human body further, thus raising the present invention plants the both effectiveness of each embodiment product.
The lutein raw material adopted in various embodiments of the present invention is import xanthophyll-oil, as DSMNutritionalProducts (DSM nutriment) produces
lutein 20%SAF (production code member 5011876); OmniActive Company
freeLuteinOilSuspension20% (ItemCode26507) etc.
Red colouring agent for food, also used as a Chinese medicine: also known as red yeast rice, is take rice as primary raw material, makes through Fermentation Condition of Monascus spp.Red colouring agent for food, also used as a Chinese medicine can suppress the synthesis of too much cholesterol in body effectively, regulates and adjusts total cholesterol level; Suppress the formation of atherosclerotic plaque, protection vascular endothelial cell; Regulate blood pressure; Suppress mouse obesity, promote mouse movement endurance, heighten the effects such as blood pool regulating power, therefore red colouring agent for food, also used as a Chinese medicine is widely used in the health functional food such as auxiliary antilipemic, aided blood pressure-lowering, have not been reported preparing the application in alleviating asthenopia health products for it.The red colouring agent for food, also used as a Chinese medicine that the present invention adopts is commercially available Hongqu powder (red colouring agent).
Vitamin A: vitamin A has another name called retinol is the constituent of the photoactive substance formed in cellula visualis.The visual performance under half-light can be maintained, promote the normal differentiation of each institutional framework of eyes, maintain normal visual performance.VAD can cause yctalopia and scheroma.
The metabolite of vitamin A is retinene and retinoic acid: 1) retinoic acid is by being combined the transcriptional expression of rear controlling gene with nuclear receptor, regulate the growth of eye and the normal differentiation of eye superficial epithelium, when VAD, the non-superficial cell in corneal epithelial cell can be made to be converted into the scaly epithelium of angling, seriously can to cause the generation of scheroma; 2) retinene participates in composition vision color base: the photoreceptor of eye is rhabdocyte in retina and cone cell.These two kinds of cells all have photopigment, namely feel the rhodopsin of the low light level and the visual violet of sense high light.Rhodopsin and visual violet are all made up of opsin and retinene.Vitamin A is sufficient, then the regeneration of rhodopsin soon and completely, therefore dark adaptation is short for recovery time; If hypovitaminosis A, then rhodopsin regeneration slowly and not exclusively, therefore dark adaptation extends recovery time, can produce yctalopia time serious.
Vitamin E: vitamin E is also known as tocopherol, being a kind of liposoluble vitamin, is one of topmost antioxidant, and biomembrane can be made to avoid peroxidatic reaction of lipid occurs, make biomembranous information transmission, permeability, enzyme activity keep normal, stop large biological molecule generation oxygen free radical injury etc.Geriatric animals replenishing vitamins E can remove the lipofuscin in the cells such as brain tissue, prevents failure of memory, reduces the generation etc. of cataract and macula retinae disease.
Formula compatibility of the present invention carries out compatibility according to lutein, red colouring agent for food, also used as a Chinese medicine, VitAVitE, vegetable oil feature separately, and effect is worked in coordination with each other, functionally mutually supports.Supplement eye desired substance by lutein, VitAVitE, improve the effect such as cell, tissue activity and play and directly act on eye, play the effect that effect alleviates the generation of the illness in eye such as each crowd's eye strain symptom, prevention prevention AMD; Improve ocular blood environment by red colouring agent for food, also used as a Chinese medicine, improve the osmotic pressure of blood, the osmotic pressure of prevention lens and eye waterproof is corresponding to be increased, and the crystalline lens caused becomes convex; Red colouring agent for food, also used as a Chinese medicine can stimulate circulation, thus promotes the absorption of the nutriment such as lutein, VitAVitE.In addition applicant is also surprised to find, and when adopting specific compatibility and proportioning, significantly can improve the adding of red colouring agent for food, also used as a Chinese medicine the dry and astringent and eye foreign body sense symptom of eye.
As can be seen here; a kind of health food with asthenopia releasing function, vision protection provided by the invention; by to the specific compatibility of each component and proportioning; create certain between each component collaborative to rent; health products are made both to have had the effect of asthenopia releasing function, vision protection; again there is auxiliary antilipemic, regulate the function of cardiovascular system.
Detailed description of the invention
In order to make those skilled in the art person understand technical scheme of the present invention better, below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1
In the present embodiment, health food active ingredient by weight percentage composition is composed of the following components: xanthophyll-oil 20%, red colouring agent for food, also used as a Chinese medicine 10%, vitamin A 0.4%, vitamin E 0.5%, corn oil 69.1%.Above-mentioned active ingredient be embedded in capsule material according to this area conventional method, make capsule, the mass ratio of active ingredient and capsule material is 1:1.8.Capsule material comprises gelatin, glycerine, water and Brown Ferric Oxide, and the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.Concrete preparation technology is techniques well known, repeats no more in the present embodiment and other embodiments.
Embodiment 2
In the present embodiment, health food active ingredient by weight percentage composition is composed of the following components: xanthophyll-oil 25%, red colouring agent for food, also used as a Chinese medicine 15%, vitamin A 0.6%, vitamin E 0.8%, soybean oil 58.6%.Above-mentioned active ingredient be embedded in capsule material according to this area conventional method, make capsule, the mass ratio of active ingredient and capsule material is 1:1.8.Capsule material comprises gelatin, glycerine, water and Brown Ferric Oxide, and the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.
Embodiment 3
In the present embodiment, health food active ingredient by weight percentage composition is composed of the following components: xanthophyll-oil 30%, red colouring agent for food, also used as a Chinese medicine 20%, retinol1 %, vitamin e1 %, rice bran oil 48%.Above-mentioned active ingredient be embedded in capsule material according to this area conventional method, make capsule, the mass ratio of active ingredient and capsule material is 1:1.8.Capsule material comprises gelatin, glycerine, water and Brown Ferric Oxide, and the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.
Test example 1:
The human feeding trial of alleviating asthenopia is carried out with the product obtained in embodiment 1:
1 materials and methods
1.1 samples: soft capsule is prepared by embodiment 1,0.3g/ grain, packing specification 30/bottle, human body recommended intake is 1/day.Tester: identical proterties, specification, without efficacy effect placebo.
1.2 study subjects: select 18 ~ 65 years old by the principle of voluntariness, have experimenter 100 example of visual fatigue symptom
1.2.1 do not include person's standard in: use eye for a long time, eyesight fatiguability person.
1.2.2 eliminator's standard
1.2.2.1 the age is under-18s or over-65s person, gestation or its women of lactation, those who are allergic to the health care products.
1.2.2.2 the severe primary diseases such as conscience kidney and hemopoietic system are associated with, mental patient.
1.2.2.3 take the article relevant with tested function in a short time, have influence on the judgement person to result.
1.2.2.4 do not meet inclusive criteria, not by the edible sample of regulation, effect or data not umbra sound effect or security judgement person cannot be judged.
1.3 experimental designs and grouping: adopt between self cross-reference and group and contrast two kinds of forms.100 experimenters are divided into test-meal group and control group at random, and test-meal group takes this health food soft capsule, and control group takes the idle effect placebo of identical proterties.
1.4 taking doses and time: each 1, every day 1 time, dose is 0.3g/ day, continuous 30 days, and experimenter cuts out medicine about improving eyesight or other health foods during test-meal.
2 observation index
Before and after following observation index experiment, each inspection once.
2.1 both effectiveness observations:
2.1.1 ordinary circumstance: detailed medical history-taking, understands the main clinic symptoms such as experimenter's ophthalmodynia, eye is swollen, photophobia, blurred vision.Observe this health food and whether have harmful effect to experimenter.
2.1.2 duration of photopic vision detects: on check table, draw the three-dimensional block diagram of triangle disposition, the every length of side of square one centimetre, local lighting 100-150LX.The distance of check table and eyes should be accustomed to remaining on suitably apart from motionless depending on thing according to experimenter, and word image is considered as photopic vision to specify that experimenter sees " product ", falls that " " be not photopic vision during word, minute is 3 minutes to product.
2.2 safety observations:
2..2.1 blood, routine urinalysis and just routine inspection: red blood cell count(RBC), hemoglobin, white blood cell count(WBC), urinates ten detections, stool microscopy.
2.2.2 Biochemical Indexes: serum cell protein ALB, total protein TP, hepatic and renal function (total bilirubin TBIL, glutamic-pyruvic transaminase ALT, urea UREA, inosine CRE), blood sugar GLU, blood fat (T-CHOL TC, triglycerides TG) index.
2.2.3 Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest
2.3 effect judges:
Effective: symptom is improved and differed by more than before and after duration of photopic vision and equal 0.1.
Invalid: symptom and duration of photopic vision are without significant change.
3 result of the tests
3.1 functional observation results
3.1.1 ordinary circumstance
Include experimenter 104 example in, be divided into test-meal group and control group at random.Get rid of experimenter 4 example, effective experimenter 100 example, test-meal group and each 50 examples of control group, experimenter tests front routine blood test, routine urinalysis, stool routine examination, hepatic and renal function, Chest X-rays, electrocardiogram, B ultrasonic etc. and checks all in normal range (NR), grouping situation is in table 1, before test-meal, two groups of subject age, sex, duration of photopic vision, equal no significant differences of eyesight (P > 0.05), have comparativity.Before and after examination trencherman test-meal, spirit, sleep, diet, stool and urine etc. are without significant change.
Before table 1 test-meal, physical data compares
P > 0.05 between test-meal group and control group
3.1.2 the change of symptom total mark:
Symptom total mark change before and after table 2 test-meal
* compare in group between P < 0.01, # group and compare P < 0.05
3.1.3 cardinal symptom improves situation:
Table 3 cardinal symptom improves situation
Be control group in ()
3.1.4 duration of photopic vision change
Duration of photopic vision change before and after table 4 test-meal
* self compare between P < 0.01, # group and compare P < 0.01
3.1.5 effect judges
Effect result of determination before and after table 5 test-meal
P < 0.05 is compared between # group
From table 2,4,5, after test, test-meal group symptom total mark is obviously improved (P < 0.01), duration of photopic vision is 0.62 ± 0.10 (P < 0.01), average duration of photopic vision improves 0.11 ± 0.08, wherein effective 24 examples, total effective rate 48.00% (P < 0.05).
3.2 safety observations results
3.2.1 blood, urine and stool routine examination safety index
Before and after table 6 test-meal, the change of blood, urine and stool routine examination safety index is compared
Before and after experiment, above-mentioned indices is all in normal range (NR).
3.2.2 Abdominal B type ultrasonography, electrocardiogram, before and after x-ray fluoroscopy of chest test-meal, test-meal group and control group are all in normal range (NR).
3.2.3 bad reaction after test-meal: be discovery bad reaction and allergic reaction situation before and after test-meal group and control group test-meal.
3.3 case depigmentation rates: test-meal group and control group are respectively 52 examples, and have 2 examples not check in the stipulated time at the end of wherein test-meal group, control group has 2 examples not check at the appointed time on time on time.Test-meal group and control group respectively have 2 examples to meet Subject Exclusion Criteria, and effective case often organizes 50 examples, and case depigmentation rate is 3.85%.
4 brief summaries
100 routine satisfactory visual fatigue patients, be divided into test-meal group and control group at random, test-meal group takes this health food after 30 days on request, duration of photopic vision is 0.62 ± 0.10, with obvious raising (P > 0.01) before test, average duration of photopic vision improves 0.11 ± 0.08, and symptom total mark is obviously improved (P < 0.01); Compare with control group, duration of photopic vision significantly improves (P < 0.01), and symptom total mark is obviously improved (P < 0.05).Wherein efficient 48.00%, compare with control group and have significant difference (P < 0.05).According to criterion, this health food has function of relieving visual fatigue.
And before and after this health food test-meal, routine blood test, routine urinalysis, just routine and blood biochemistry index, all in normal range (NR), have no irritated and other bad reaction.Illustrate that this health food has no adverse effects to experimenter is healthy.
Test example 2:
Carry out improving the dry and astringent and foreign body sensation human feeding trial of eye with the product obtained in embodiment 1:
1 materials and methods
1.1 samples: soft capsule is prepared by embodiment 1,0.3g/ grain, packing specification 30/bottle, human body recommended intake is 1/day.
Tester:
Positive control 1: xanthophyll-oil 20%, red colouring agent for food, also used as a Chinese medicine 30%, vitamin A 0.4%, vitamin E 0.5%, corn oil 49.1%; Make capsule, the composition of the quality of active ingredient and capsule material when capsule material is with embodiment 1.0.3g/ grain, packing specification 30/bottle, human body recommended intake is 1/day.
Positive control 2: xanthophyll-oil 20%, red colouring agent for food, also used as a Chinese medicine 5%, vitamin A 0.4%, vitamin E 0.5%, corn oil 74.1%.Make capsule, the composition of the quality of active ingredient and capsule material when capsule material is with embodiment 1.0.3g/ grain, packing specification 30/bottle, human body recommended intake is 1/day.
Blank thing: identical proterties, specification, without efficacy effect placebo.
1.2 study subjects: select 18 ~ 65 years old by the principle of voluntariness, have experimenter 100 example of visual fatigue symptom
1.2.1 do not include person's standard in: use eye for a long time, eyesight fatiguability person.
1.2.2 eliminator's standard
1.2.2.1 the age is under-18s or over-65s person, gestation or its women of lactation, those who are allergic to the health care products.
1.2.2.2 the severe primary diseases such as conscience kidney and hemopoietic system are associated with, mental patient.
1.2.2.3 take the article relevant with tested function in a short time, have influence on the judgement person to result.
1.2.2.4 do not meet inclusive criteria, not by the edible sample of regulation, effect or data not umbra sound effect or security judgement person cannot be judged.
1.3 experimental designs and grouping: adopt between self cross-reference and group and contrast two kinds of forms.100 experimenters are divided into test-meal group, positive controls 1, positive controls 2 and blank group at random, and test-meal group takes this health food soft capsule, and positive controls takes positive control 1,2, and blank group takes the idle effect placebo of identical proterties.
1.4 taking doses and time: each 1, every day 1 time, dose is 0.3g/ day, continuous 30 days, and experimenter cuts out medicine about improving eyesight or other health foods during test-meal.
2 observation index
Before and after following observation index experiment, each inspection once.
2.1 both effectiveness observations:
2.1.1 ordinary circumstance: detailed medical history-taking, understanding experimenter eye is dry and astringent, foreign body sensation main clinic symptoms.Observe this health food and whether have harmful effect to experimenter.
2.2 effects judge:
Effective: symptom is improved.
Invalid: symptom is without significant change.
3 result of the tests
3.1 functional observation results
3.1.1 ordinary circumstance
Include experimenter 206 example in, be divided into test-meal group and control group at random.Get rid of experimenter 6 example, effective experimenter 200 example, test-meal group, positive controls 1,2, each 50 examples of blank group, experimenter tests front routine blood test, routine urinalysis, stool routine examination, hepatic and renal function, Chest X-rays, electrocardiogram, B ultrasonic etc. and checks all in normal range (NR),, two groups of subject age, sex, duration of photopic vision, equal no significant differences of eyesight (P > 0.05) before test-meal, there is comparativity.Before and after examination trencherman test-meal, spirit, sleep, diet, stool and urine etc. are without significant change.
Before table 7 test-meal, physical data compares
P > 0.05 between test-meal group and control group
3.1.2 cardinal symptom improves situation:
Table 8 cardinal symptom improves situation
4, brief summary
Shown from the result of table 8, the present invention, after with the addition of the red colouring agent for food, also used as a Chinese medicine of certain content, significantly can improve the dry and astringent and foreign body sensation symptom of eye simultaneously.
Test example 3:
The human feeding trial of auxiliary antilipemic is carried out with the product obtained in embodiment 1:
1 materials and methods
1.1 samples: soft capsule is prepared by embodiment 1,0.3g/ grain, packing specification 30/bottle, human body recommended intake is 1/day.Tester: identical proterties, specification, without efficacy effect placebo.
1.2 study subjects: by the principle of voluntariness select 18 ~ 65 years old, simple dyslipidemia experimenter 120 example.
1.2.1 do not include person's standard in: the crowd of simple dyslipidemia, keep usual diet, take a blood sample half a year 2 times, twice serum total cholesterol (TC) is >=5.2mmol/L, or twice serum triglyceride (TG) >=1.65mmol/L.
1.2.2 eliminator's standard
With the 1.2.2 in test example 1
1.3 experimental designs and grouping: adopt between self cross-reference and group and contrast two kinds of forms.120 experimenters are divided into test-meal group and control group at random, and test-meal group takes this health food soft capsule, and control group takes the idle effect placebo of identical proterties.
1.4 taking doses and time: each 1, every day 1 time, dose is 0.3g/ day, continuous 30 days, and experimenter cuts out medicine about auxiliary antilipemic or other health foods during test-meal.
2 observation index
Before and after following observation index experiment, each inspection once.
2.1 both effectiveness observations: serum total cholesterol (TC) level and reduction percentage, triglycerides (TG) level and reduction percentage, HDL-C (HDL-C) level and ascensional range.
2.2 safety observations: comprise routine blood test, blood pressure, hepatic and renal function, Chest X-rays, electrocardiogram, Abdominal B type ultrasonography etc.
2.3 effects judge:
Effective: TC reduces > 10%; TG reduces > 15%.Invalid: not reach effective standard person.
3 result of the tests
3.1 ordinary circumstance
Test-meal group and control group finally enter the number of effectively adding up and are respectively 59 and 58 examples.Before test-meal, the age, mental status, sleep quality, diet situation etc. of test-meal group and control group crowd is basically identical, and the Chest X-rays of two groups of crowds, electrocardiogram, Abdominal B type ultrasonography check result are showed no obvious abnormalities.Serum TC, TG and HDL-C there are no significant difference (P > 0.05)
Before table 9 test-meal, physical data compares
3.2 samples are on the impact of people with hyperlipidemia efficiency index:
The serum TC comparision contents of two groups of crowds before and after table 10 test-meal
The serum TG comparision contents of two groups of crowds before and after table 11 test-meal
3.3 effects judge
Effect result of determination before and after table 12 test-meal
3.4 safety observations results
The check results such as before and after implementing, the heart rate of test-meal group and control group two groups of crowds, systolic pressure, diastolic pressure are equal, routine blood test, routine urinalysis, just routine, blood Main Biochemical are all in normal range (NR).
3.2.3 bad reaction after test-meal: be discovery bad reaction and allergic reaction situation before and after test-meal group and control group test-meal.
3.3 case depigmentation rates: test-meal group and control group are respectively 60 examples, have 3 routine experimenters lost to follow-up and disallowable at the end of wherein test-meal group.The number that test-meal group and control group finally enter effectively statistics is respectively 59 and 58 examples, and case depigmentation rate is 2.5%.
4 brief summaries
117 routine satisfactory people with hyperlipidemia (control group 58 example: man 29 example, female 29 example; Test-meal group 59 example: man 29 example, female 30 example) carry out test-meal test.Test-meal group takes sample (every day 1 time continuously, each 1) after 30 days, serum TC, TG drop-out value are obviously greater than control group, compare before and after self test and with more all there is between control group group significant difference (P < 0.01), and before and after control group test self TC, TG value difference different there are no significant (P > 0.05); Test-meal group serum TC, TG are average respectively declines 11.08% and 15.75%, and control group serum TC, TG raise 1.04% and 0.96% respectively; Test-meal group total effective rate is 50.9%, is significantly higher than the 1.7%. of control group as can be seen here, and this sample has the function of auxiliary antilipemic.
And before and after this health food test-meal, routine blood test, routine urinalysis, the just detected value such as routine and blood biochemistry index, all in normal range (NR), have no irritated and other bad reaction.Illustrate that this health food has no adverse effects to experimenter is healthy.
Above the health food of a kind of alleviating asthenopia provided by the present invention is described in detail.Apply specific case herein to set forth principle of the present invention and embodiment, the explanation of above embodiment just understands core concept of the present invention for helping.It should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention, some improvement and modification can also be carried out to the present invention.These improve and modify and also should fall in the protection domain of the claims in the present invention.
Claims (9)
1. one kind has the health food of alleviating asthenopia and vision protection function; it is characterized in that; its active ingredient comprises following component by weight percentage: xanthophyll-oil 20% ~ 30%; red colouring agent for food, also used as a Chinese medicine 10% ~ 20%; vitamin A 0.4% ~ 1%, vitamin E 0.5% ~ 1% and vegetable oil 48% ~ 69.1%.
2. the health food with alleviating asthenopia and vision protection function according to claim 1; it is characterized in that, described vegetable oil is any one or a few the combination in soybean oil, sunflower oil, olive oil, safflower oil, rice bran oil and maize germ oil.
3. the health food with alleviating asthenopia and vision protection function according to claim 1, is characterized in that, described vegetable oil is corn oil; the percentage by weight of each component is: xanthophyll-oil 20%; red colouring agent for food, also used as a Chinese medicine 10%, vitamin A 0.4%, vitamin E 0.5% and vegetable oil 69.1%.
4. the health food with alleviating asthenopia and vision protection function according to claim 1, is characterized in that, described vegetable oil is soybean oil; the percentage by weight of each component is: xanthophyll-oil 25%; red colouring agent for food, also used as a Chinese medicine 15%, vitamin A 0.6%, vitamin E 0.8% and soybean oil 58.6%.
5. the health food with alleviating asthenopia and vision protection function according to claim 1, is characterized in that, described vegetable oil is rice bran oil; the percentage by weight of each component is: xanthophyll-oil 30%; red colouring agent for food, also used as a Chinese medicine 20%, retinol1 %, vitamin e1 % and rice bran oil 48%.
6. the health food with alleviating asthenopia and vision protection function according to claim 1-5, is characterized in that, the formulation of health food is capsule, and the mass ratio of active ingredient and capsule material is: 1:1.8.
7. the health food with alleviating asthenopia and vision protection function according to claim 6; it is characterized in that, described capsule material comprises gelatin, glycerine; water and Brown Ferric Oxide, the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.
8. one kind has the health food of alleviating asthenopia and vision protection function, it is characterized in that, comprise active ingredient and capsule material, described active ingredient comprises following component by weight percentage: xanthophyll-oil 20% ~ 30%, red colouring agent for food, also used as a Chinese medicine 10% ~ 20%, vitamin A 0.4% ~ 1%, vitamin E 0.5% ~ 1% and vegetable oil 48% ~ 69.1%; The mass ratio of described active ingredient and capsule material is: 1:1.8.
9. the health food with alleviating asthenopia and vision protection function according to claim 8; it is characterized in that, described capsule material comprises gelatin, glycerine; water and Brown Ferric Oxide, the mass ratio of each component is: gelatin: glycerine: water: Brown Ferric Oxide=1.0:0.5:0.9:0.016.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510963918.0A CN105520137B (en) | 2015-12-21 | 2015-12-21 | It is a kind of that there is the health food alleviated visual fatigue and protect visual function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510963918.0A CN105520137B (en) | 2015-12-21 | 2015-12-21 | It is a kind of that there is the health food alleviated visual fatigue and protect visual function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105520137A true CN105520137A (en) | 2016-04-27 |
| CN105520137B CN105520137B (en) | 2018-03-06 |
Family
ID=55763048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510963918.0A Active CN105520137B (en) | 2015-12-21 | 2015-12-21 | It is a kind of that there is the health food alleviated visual fatigue and protect visual function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105520137B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919118A (en) * | 2016-05-03 | 2016-09-07 | 北京东方红航天生物技术股份有限公司 | Health-care food with antioxidant function |
| CN108888682A (en) * | 2018-09-12 | 2018-11-27 | 西安力邦制药有限公司 | A kind of improving eyesight eyeshield composition |
| CN108992544A (en) * | 2018-09-12 | 2018-12-14 | 西安力邦制药有限公司 | A kind of Chinese medicine composition for preventing and treating eye disease |
| CN109222102A (en) * | 2018-09-26 | 2019-01-18 | 烟台燕园科玛健康产业有限公司 | A kind of health food for alleviating eye fatigue composition and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007050521A2 (en) * | 2005-10-26 | 2007-05-03 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
| CN101766307A (en) * | 2010-03-02 | 2010-07-07 | 中国农业科学院油料作物研究所 | Health food with function of relieving visual fatigue and preparation method thereof |
| CN101869237A (en) * | 2010-06-04 | 2010-10-27 | 刘小松 | Rice/flour starch food containing proanthocyanidin and anthocyanin |
| CN104824675A (en) * | 2015-05-13 | 2015-08-12 | 宁波北仑戌鸿农业科技有限公司 | Eyesight improving lutein capsule |
| CN105030877A (en) * | 2015-07-13 | 2015-11-11 | 北京世纪合辉医药科技股份有限公司 | Healthcare food for relieving asthenopia and preparation method thereof |
-
2015
- 2015-12-21 CN CN201510963918.0A patent/CN105520137B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007050521A2 (en) * | 2005-10-26 | 2007-05-03 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
| CN101766307A (en) * | 2010-03-02 | 2010-07-07 | 中国农业科学院油料作物研究所 | Health food with function of relieving visual fatigue and preparation method thereof |
| CN101869237A (en) * | 2010-06-04 | 2010-10-27 | 刘小松 | Rice/flour starch food containing proanthocyanidin and anthocyanin |
| CN104824675A (en) * | 2015-05-13 | 2015-08-12 | 宁波北仑戌鸿农业科技有限公司 | Eyesight improving lutein capsule |
| CN105030877A (en) * | 2015-07-13 | 2015-11-11 | 北京世纪合辉医药科技股份有限公司 | Healthcare food for relieving asthenopia and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919118A (en) * | 2016-05-03 | 2016-09-07 | 北京东方红航天生物技术股份有限公司 | Health-care food with antioxidant function |
| CN108888682A (en) * | 2018-09-12 | 2018-11-27 | 西安力邦制药有限公司 | A kind of improving eyesight eyeshield composition |
| CN108992544A (en) * | 2018-09-12 | 2018-12-14 | 西安力邦制药有限公司 | A kind of Chinese medicine composition for preventing and treating eye disease |
| CN109222102A (en) * | 2018-09-26 | 2019-01-18 | 烟台燕园科玛健康产业有限公司 | A kind of health food for alleviating eye fatigue composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105520137B (en) | 2018-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7887847B2 (en) | Nutritional supplement for treatment of ocular diseases | |
| CN103735733B (en) | A kind of compound preparation containing lutein ester and preparation method thereof | |
| CN101766307B (en) | Health food with function of relieving visual fatigue and preparation method thereof | |
| EP2138055B1 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
| CN108157568A (en) | A kind of Combined candy for alleviating visual fatigue and its preparation method and application | |
| CN102763847B (en) | Health-care food with function of relieving visual fatigue and preparation method thereof | |
| CN101703559B (en) | Medicinal composition with function of relieving visual fatigue and preparation method thereof | |
| CN102225087A (en) | Xanthophyll compound preparation with powerful eye-protecting effect | |
| JP2008271878A (en) | Novel food and drink | |
| CN103566049A (en) | Composition for improving density of macular pigment in eyes and preventing or treating age-related macular degeneration | |
| CN105520137B (en) | It is a kind of that there is the health food alleviated visual fatigue and protect visual function | |
| CN104147081A (en) | Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof | |
| CN103300373A (en) | Lutein and procyanidine composite soft capsule and preparation method thereof | |
| CN106889617A (en) | A kind of eye health-care edible, its preparation method and application | |
| CN104474018A (en) | Health-care soft capsule for relieving asthenopia | |
| CN100574772C (en) | A kind of soft capsule that contains phylloxanthin and preparation method thereof | |
| CN110169484A (en) | A kind of blueberry lutein ester pressed candy and preparation method thereof | |
| CN103316032B (en) | Compositions containing hydroxytyrosol and application thereof | |
| CN106617055A (en) | Eye-protecting healthcare food for relieving degenerative eye diseases and preparation method thereof | |
| CN103798808A (en) | Nutrient formula and application thereof to food or medicine for reliving asthenopia | |
| CN101416741A (en) | Health-care food for relieving visual fatigue | |
| CN106692187A (en) | Composition for improving visuognosis persistence and protecting eye health | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN105412354A (en) | Eye protecting lollipop containing lycium ruthenicum Murr. | |
| CN109010790A (en) | A kind of composition and its application for improving eye strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |